Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study

NCT04575415 · clinicaltrials.gov ↗

UNKNOWN

Status

272

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Bevacizumab
DRUG: Erlotinib
DRUG: Gefitinib
DRUG: Icotinib
DRUG: Afatinib
DRUG: Dacomitinib
DRUG: Osimertinib

Sponsor

Guangdong Association of Clinical Trials